UK analytical services expert, Quotient Bioscience has received a significant equity investment from TA Associates to help further the firm’s acquisition-led and organic growth strategy.
Canada’s Patheon put in another quarter of robust revenues growth in its third quarter, which coupled with cost-reduction measures helped the firm trim its net loss to $14.7m, down 75 per cent on a year ago.
Growth in licensing deals between large drugmakers companies and their smaller, research-based counterparts continued apace in 2007, but the average total value of each deal has started to fall.
Recent developments in the clinical research sector include an acquisition by Canada’s Algorithme, a Dutch CRO looking to push into the North American market, and a £20m boost for UK clinical research.
Drug delivery specialist BioAlliance Pharma says that its decision to focus on the oncology and infectious disease markets helped it reduce its half-year 2008 losses.
US fine chemical company Sigma-Aldrich said this morning that subsidiary SAFC Pharma has kicked off a $30m expansion plan for its active high-potency pharmaceutical ingredient (API) manufacturing facility in Madison, Wisconsin.
Caliper Life Sciences has launched two new kinase profiling services as well as new assay kits that aim to provide researchers with a better understanding of their kinase inhibitor drug candidates.
in-PharmaTechnologist.com's periodic round-up of developments and deals in the pharmaceutical manufacturing space, includes news on 3M and Ligacon, Dishman, Stiefel and Barrier and Forbes.
UK and Swedish researchers have developed a system that eliminates the need for antibiotics and resistance genes in the engineering of biopharmaceutical products, making the process both safer and less costly.
bioMerieux hopes that its new specially-packaged growth media products will help it “clean up” in the pharmaceutical industry’s lucrative sterility testing market
UK-based polymer technology specialist Chromatide and Akzo Nobel's Separation Products (SP) unit are teaming to develop a HPLC media for purification applications in the drug manufacturing industry.
Japan’s Shionogi is paying $1.4bn (€959m) for US drugmaker Sciele Pharma as part of a plan to strengthen its sales position in the country’s $286bn a year drug market.
Merck & Co has been accused of carrying out clinical trials of its Vioxx (rofecoxib) painkiller that were designed primarily for marketing purposes rather than to answer a clinical hypothesis.
Contrary to fears, the European Union’s Clinical Trials Directive has not had an inhibitory effect on the number of studies carried out by publicly-funded researchers, at least in Denmark.
Contract services firm Marksans Pharmaceutical says that the RPS 1bn (€15.4m) acquisition of UK generics group Relonchem will expand its distribution network and build its presence in the European market.
US trial firm ACRI and contract research organisation (CRO) Clinesian have teamed up to target the pharmaceutical sector’s ever growing demand for integrated clinical development capacity.
Canada’s PharmEng International almost tripled its turnover in the second quarter, as its acquisition of a Pfizer manufacturing facility at the end of 2007 transformed sales at contract manufacturing facility Keata Pharma.
A milestone payment from Bristol-Myers Squibb for the successful advancement of a project into clinical development, along with strong sales by its contract research and manufacturing services unit, prompted Albany Molecular Research Inc (AMRI) to hike...